Literature DB >> 11103821

Clonal selection versus genetic instability as the driving force in neoplastic transformation.

M Chow1, H Rubin.   

Abstract

Recent clonal studies of spontaneous neoplastic transformation in cell culture indicate that it develops at confluence in a small minority of individual clonal populations before it does in the uncloned parental culture. Either preferential selection of spontaneous variants or genetic destabilization in clones can be inferred to explain the result. In the present experiments, using a subline of NIH 3T3 cells that is relatively refractory to transformation, we demonstrate unequivocally that transformed foci appear under selective conditions in some clones long before there is any sign of neoplastic change in the polyclonal culture from which they were derived. Because the transformed cells that appear in the susceptible clones are not inhibited in the size or number of foci formed on a confluent background of the uncloned parental population, the genetic events underlying transformation must occur much less frequently in the latter. This disparity can be accounted for by the much larger number of selectable cells in the susceptible clones at confluence than in the parental culture, where such cells are a minority. The preferential transformation exhibited by experimental isolation and expansion of susceptible clones accords with evidence from various sources that neoplastic transformation in culture is a multistep process dependent primarily on selection of spontaneously occurring genetic variants. There is no necessity to posit a significant role for genetic destabilization in neoplastic transformation. These considerations bolster computer models of human cancer that implicate selective expansion of rogue clones rather than genetic instability as the driving force in the origin of most tumors. Both the genetics of the selected clone and the epigenetics of the selective environment would then contribute to tumor development.

Entities:  

Mesh:

Year:  2000        PMID: 11103821

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

2.  Evolution in biological and nonbiological systems under different mechanisms of generation and inheritance.

Authors:  Isaac Salazar-Ciudad
Journal:  Theory Biosci       Date:  2008-10-23       Impact factor: 1.919

Review 3.  Biomarkers and the genetics of early neoplastic lesions.

Authors:  Sudhir Srivastava; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 4.  Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders.

Authors:  Sara K Story; Michael K Schowalter; Larisa J Geskin
Journal:  Oncologist       Date:  2013-02-21

Review 5.  Cancer models, genomic instability and somatic cellular Darwinian evolution.

Authors:  Mark P Little
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

6.  Evaluation of Three Devices for the Isolation of the Stromal Vascular Fraction from Adipose Tissue and for ASC Culture: A Comparative Study.

Authors:  Jonathan Rodriguez; Anne-Sophie Pratta; Nacira Abbassi; Hugo Fabre; Fanny Rodriguez; Cyrille Debard; Jacqueline Adobati; Fabien Boucher; Frédéric Mallein-Gerin; Céline Auxenfans; Odile Damour; Ali Mojallal
Journal:  Stem Cells Int       Date:  2017-02-22       Impact factor: 5.443

7.  Methylation kinetics and CpG-island methylator phenotype status in colorectal cancer cell lines.

Authors:  Dominik Wodarz; C Richard Boland; Ajay Goel; Natalia L Komarova
Journal:  Biol Direct       Date:  2013-06-11       Impact factor: 4.540

8.  Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells.

Authors:  M Fojtova; V Boudny; A Kovarik; L Lauerova; L Adamkova; K Souckova; J Jarkovsky; J Kovarik
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.